

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

Re: Attorney Docket No. DB000670-001

J1011 U.S. PTO
10/04/360
01/11/02

In re application of: Brima et al.

Serial No.: Filed Herewith

Group Art Unit:

Filed: Herewith

Examiner:

For: NOVEL HYDROTALCITES SYNTHESSES, AND USES

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This Information Disclosure Statement is filed in accordance with 37 C.F.R.

§ § 1.56, 1.97 and 1.98. The items listed on the enclosed Form PTO-1449 may be deemed to be pertinent to the above-identified application and are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

1. () Items listed on the enclosed Form PTO-1449 are not in the English language.
 - () For each of the following items, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed: _____
 - () For each of the following items, a concise explanation of that item is incorporated in the specification of the above-identified application: _____
 - () For each of the following items, a corresponding U.S. or other English-language patent is enclosed. Please consider the U.S. or other English-language patent in accordance with the procedure set forth in MPEP § 609: _____

2. ☐ Any copy of the items listed on the enclosed Form PTO-1449 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark office in Application Serial No. _____, filed _____, of which the present application is a:

- ☐ Continuation application,
- ☐ Divisional application, or
- ☐ Continuation-In-Part application

filed under 37 CFR § 1.53(b) or (d).

3. ☒ Submission in Accordance with 37 CFR § 1.97(b).

This Information Disclosure Statement is being filed

- ☒ Within three months of the filing date of a national application;
- ☐ Within three months of the date of entry of the national stage in an international application; or
- ☐ Before the mailing date of a first Office action on the merits,

and NO FEE is due for consideration of this Information Disclosure Statement.

4. ☐ Submission in Accordance with 37 CFR 1.97(c).

This Information Disclosure Statement is being filed before the first mailing date of either

- ☐ A final action under § 1.113; or
- ☐ A notice of allowance under § 1.311,
- ☐ A fee is due for consideration of this Information Disclosure Statement and the fee is paid below; or
- ☐ This Information Disclosure Statement is accompanied by one of the certifications pursuant to 37 CFR § 1.97(e), and NO FEE is due for consideration of this Information Disclosure Statement.

5. ☐ Submission in Accordance with 37 CFR 1.97(d).

This Information Disclosure Statement is being filed after the mailing date of either

- () A final action under § 1.113; or
- () A notice of allowance under § 1.311,

whichever comes first, but before payment of the issue fee, and is accompanied by

- a. One of the certifications pursuant to 37 CFR § 1.97(e), which is set forth below;
- b. The attached petition requesting consideration of this Information Disclosure Statement; and
- c. The petition fee under 37 CFR § 1.17(i)(1), which is paid below.


6. Certification Pursuant to 37 CFR 1.97(e).

- () The undersigned certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application not more than three months prior to the filing of this Information Disclosure Statement; or
- () The undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, or to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

7. Fee Payment Being Made.

- () Enclosed
 - () \$240.00 fee for submission under 37 CFR § 1.97(c).
- () A check in the amount of \$_____ to cover the fee payment is enclosed.
- () Charge the fee to Deposit Account No. 50-0436. A duplicate copy of this communication is attached.
- (x) The Commissioner is hereby authorized to charge payment of any additional fees associated with this Information Disclosure Statement or credit any overpayment to Deposit Account No. 50-0436. A duplicate copy of this communication is enclosed.

Respectfully submitted,



Matthew P. McWilliams
Reg. No. 46,922

PEPPER HAMILTON LLP
3000 Two Logan Square
Eighteenth and Arch Streets
Philadelphia, PA 19103-2799
(215) 981- 4442
Agent for Applicants

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Docket Number (Optional) DB000670-001		Application Number Filed Herewith								
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Applicant:										
				Issue/Filing Date: Filed Herewith		Group Art Unit N/A								
U.S. PATENT DOCUMENTS														
Examiner Initial	Cite #	Document Number								Date	Name	Class	Subclass	Filing Date If Appropriate
	AA	5	0	6	4	8	0	4	Nov. 12, 1991	Soo et al.				
	AB	5	3	9	9	3	2	9	Mar. 21, 1995	Schutz et al.				
	AC	5	5	0	7	9	8	0	Apr. 16, 1996	Kelkar et al.				
	AD	5	5	1	8	7	0	4	May 21, 1996	Kelkar et al.				
	AE	5	5	7	8	2	8	6	Nov. 26, 1996	Martin et al.				
	AF	5	7	2	8	3	6	6	Mar. 17, 1998	Martin et al.				
	AG	5	9	1	0	5	2	3	Jun. 8, 1999	Hudson				
	AH	5	9	7	3	0	5	3	Oct. 26, 1999	Usuki et al.				
FOREIGN PATENT DOCUMENTS														
		Document Number								Name of Patentee or Applicant	Country	Date of Publication of Cited Document MM-DD-YYYY	Translation	
													Yes	No.
	AI	1	0	0	3	6	5	8	9	Shingenori et al.	JP		Abstract	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)														
Examiner											Date Considered			

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.

(Form PTO-1449)